Conecte-se

Bibliografias temáticas / RNA signature

Índice

Artigos de revistas

Literatura científica selecionada sobre o tema "RNA signature"

Autor: Grafiati

Publicado: 12 de abril de 2025

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Consulte a lista de atuais artigos, livros, teses, anais de congressos e outras fontes científicas relevantes para o tema "RNA signature".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Artigos de revistas sobre o assunto "RNA signature"

1

Liu, Jie, Wenmin Deng, Zhiwen Xiao, Xiaofeng Huang, Minmin Lin, and Zhen Long. "Identification of RNA Modification-Associated Alternative Splicing Signature as an Independent Factor in Head and Neck Squamous Cell Carcinoma." Journal of Immunology Research 2022 (September 13, 2022): 1–19. http://dx.doi.org/10.1155/2022/8976179.

Texto completo da fonte

Resumo:

Objective. Head and neck squamous cell carcinoma (HNSCC) is a highly heterotopic malignant tumor. Alternative splicing (AS) and RNA modification have been reported to be involved in tumorigenesis. Therefore, we constructed RNA modification-associated AS (RMA-AS) signature model to predict the prognosis of HNSCC. Methods. AS events and RNA-modified gene expression information were downloaded from TCGA-HNSCC database. Univariate Cox regression analysis was employed for analyzing prognosis-related AS events. RMA-AS events were obtained by constructing a coexpression network between RNA modificati

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Stupnikov, Alexey, Paul G. O’Reilly, Caitriona E. McInerney, et al. "Impact of Variable RNA-Sequencing Depth on Gene Expression Signatures and Target Compound Robustness: Case Study Examining Brain Tumor (Glioma) Disease Progression." JCO Precision Oncology, no. 2 (November 2018): 1–17. http://dx.doi.org/10.1200/po.18.00014.

Texto completo da fonte

Resumo:

Purpose Gene expression profiling can uncover biologic mechanisms underlying disease and is important in drug development. RNA sequencing (RNA-seq) is routinely used to assess gene expression, but costs remain high. Sample multiplexing reduces RNA-seq costs; however, multiplexed samples have lower cDNA sequencing depth, which can hinder accurate differential gene expression detection. The impact of sequencing depth alteration on RNA-seq–based downstream analyses such as gene expression connectivity mapping is not known, where this method is used to identify potential therapeutic compounds for

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Albitar, Maher, Sally Agersborg, Ahmad Charifa, et al. "Establishing Distinct Cytokine Signatures Differentiating between Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Chip Using Bone Marrow RNA or Cell-Free RNA (cfRNA)." Blood 144, Supplement 1 (2024): 4295. https://doi.org/10.1182/blood-2024-203870.

Texto completo da fonte

Resumo:

Cytokines are essential for various immune functions and the overall inflammatory response to myeloid neoplasms in bone marrow. They play a major role in bone marrow microenvironment in normal and abnormal hematopoiesis. Cytokines exert their functions by interacting with their receptors, and full evaluation of the cytokines' roles requires evaluating their receptors as well. Using next generation sequencing (NGS) and machine learning, we measured the expression of 36 cytokines/chemokines and cytokine receptors in the bone marrow (BM) of patients with acute myeloid leukemia (AML), myelodysplas

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Al Mahi, Naim, Erik Y. Zhang, Susan Sherman, Jane J. Yu, and Mario Medvedovic. "Connectivity Map Analysis of a Single-Cell RNA-Sequencing -Derived Transcriptional Signature of mTOR Signaling." International Journal of Molecular Sciences 22, no. 9 (2021): 4371. http://dx.doi.org/10.3390/ijms22094371.

Texto completo da fonte

Resumo:

In the connectivity map (CMap) approach to drug repositioning and development, transcriptional signature of disease is constructed by differential gene expression analysis between the diseased tissue or cells and the control. The negative correlation between the transcriptional disease signature and the transcriptional signature of the drug, or a bioactive compound, is assumed to indicate its ability to “reverse” the disease process. A major limitation of traditional CMaP analysis is the use of signatures derived from bulk disease tissues. Since the key driver pathways are most likely dysregul

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Lu, Zhihao, Huan Chen, Shuang Li, et al. "A RNA signature predicts outcomes in immune checkpoint blockade treated gastrointestinal cancer patients." Journal of Clinical Oncology 37, no. 15_suppl (2019): e14071-e14071. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14071.

Texto completo da fonte

Resumo:

e14071 Background: Cancer therapy has been greatly revolutionized in recent years by the conceptual developments in the field of cancer immunology. Growing evidence support the utility of immune checkpoint inhibition (ICB) in gastrointestinal (GI) cancer. However, a central question lies in understanding how therapeutic responsiveness is predicted. Methods: To address this, we evaluated tumor FFPE specimens from 97 patients who received ICB treatment. All patients were randomly assigned into discovery (60%) and validation (40%) cohorts. Tumor RNA before ICB treatment was analyzed on a multiple

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Li, Chenyang, Thinh T. Nguyen, Jian-Rong Li, et al. "Abstract 97: Multiregional profiling revealed intra-tumor transcriptomic heterogeneity associated with the prognosis in non-small cell lung cancer." Cancer Research 83, no. 7_Supplement (2023): 97. http://dx.doi.org/10.1158/1538-7445.am2023-97.

Texto completo da fonte

Resumo:

Abstract Introduction: Intratumor heterogeneity (ITH) describes the distinct tumor cell populations and microenvironments within the same tumor, which may profoundly impact cancer evolution and clinical outcomes. Non-small cell lung cancer (NSCLC) is not only a genetically diverse disease but also has high transcriptomic heterogeneity (RNA-ITH). The RNA-ITH limits the reproducibility of expression-based prognostic models, which is poorly understood. Methods: To address the issue, we investigated the effect of RNA-ITH on prognosis at both gene and signature levels using multiregional RNA-seq da

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Wen, Huaming, Ryan A. Gallo, Xiaosheng Huang, et al. "Incorporating Differential Gene Expression Analysis with Predictive Biomarkers to Identify Novel Therapeutic Drugs for Fuchs Endothelial Corneal Dystrophy." Journal of Ophthalmology 2021 (June 28, 2021): 1–8. http://dx.doi.org/10.1155/2021/5580595.

Texto completo da fonte

Resumo:

Purpose. Based on the differential gene expression analysis for predictive biomarkers with RNA-Sequencing data from Fuchs endothelial corneal dystrophy (FECD) patients, we are aiming to evaluate the efficacy of Library of Integrated Network-based Cellular Signatures (LINCS) perturbagen prediction software to identify novel pharmacotherapeutic targets that can revert the pathogenic gene expression signatures and reverse disease phenotype in FECD. Methods. A publicly available RNA-seq dataset was used to compare corneal endothelial specimens from controls and patients with FECD. Based on the dif

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Wang, Kang, Yajing Zhu, Ioannis Zerdes, et al. "Abstract PO2-07-06: Multimodal learning predictor of HER2-positive breast cancer therapy response in the randomized PREDIX HER2 trial." Cancer Research 84, no. 9_Supplement (2024): PO2–07–06—PO2–07–06. http://dx.doi.org/10.1158/1538-7445.sabcs23-po2-07-06.

Texto completo da fonte

Resumo:

Abstract Background: The PREDIX HER2 trial, compared six courses of docetaxel, trastuzumab, and pertuzumab (DTP) vs. trastuzumab emtansine (T-DM1) as neoadjuvant treatment for HER2-positive breast cancer (BC). Similar rates of pathologic complete response (pCR) were seen. Methods: Clinicopathological, shallow whole-genome sequencing (CUTseq, n=176), whole exome sequencing (WES, n=192), and RNA-sequencing (RNA-seq, n=187) data were generated using fresh-frozen baseline core biopsies. Potential tumor intrinsic resistance factors and microenvironment components were quantified by multi-omics anal

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

Erbe, Rossin, Michelle M. Stein, Tim A. Rand, and Justin Guinney. "Abstract 2281: A tumor-intrinsic signature involving immunosuppression via MIF-CD74 signaling is associated with overall survival in ICT-treated lung adenocarcinoma." Cancer Research 84, no. 6_Supplement (2024): 2281. http://dx.doi.org/10.1158/1538-7445.am2024-2281.

Texto completo da fonte

Resumo:

Abstract Introduction: Immune checkpoint therapies (ICT) have changed cancer care, yielding robust and durable responses in a subset of patients. Identifying patients who are likely to respond to ICT remains an ongoing challenge. In addition, only a portion of patients with clinical biomarkers respond to therapy. Signatures of RNA expression have been developed to predict response, the majority of which focus on T-cell and cytotoxicity markers, yet have been unable to substantially improve outcome predictions. Here, we present a RNA signature that instead describes tumor-intrinsic immune resis

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Qiu, Lipeng, Tao Wang, Qi Ge, et al. "Circular RNA Signature in Hepatocellular Carcinoma." Journal of Cancer 10, no. 15 (2019): 3361–72. http://dx.doi.org/10.7150/jca.31243.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Mais fontes

Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!